search
Back to results

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

Primary Purpose

Merkel Cell Carcinoma

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
KRT-232
Avelumab
Sponsored by
Kartos Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Merkel Cell Carcinoma focused on measuring navtemadlin (KRT-232)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • For Cohort 1, 3 and 4 patients must have failed treatment with at least one PD-1 inhibitor or PD-L1 inhibitor for metastatic MCC
  • For Cohort 2, patients must not have received any anti-PD-1 or anti-PD-L1 therapy
  • For Cohort 3, patients must not have received any prior chemotherapy
  • For Cohort 4, patients must have received at least one prior line of chemotherapy
  • ECOG performance status of 0 to 1
  • Histologically confirmed MCC. Disease must be measurable, with at least 1 measurable lesion by RECIST 1.1
  • MCC expressing p53WT based on any CLIA or test approved by local health authority or a validated test (Cohort 1 and 2)
  • MCC expressing p53WT based Central Lab test (Cohort 3 and 4)
  • Adequate hematological, hepatic, and renal functions

Exclusion Criteria:

  • For Cohort 2, subjects must not have autoimmune disease, medical conditions requiring systemic immunosuppression, prior stem cell transplant, or active infection with HBV or HCV.
  • Patients previously treated with MDM2 antagonist therapies or p53-directed therapies
  • History of major organ transplant
  • Patients with known central nervous system (CNS) metastases that are previously untreated
  • Grade 2 or higher QTc prolongation (>480 milli-seconds per NCI-CTCAE criteria, version 5.0)

Sites / Locations

  • University of Colorado Anschutz Medical CampusRecruiting
  • Miami Cancer InstituteRecruiting
  • MoffittRecruiting
  • Northwestern Memorial HospitalRecruiting
  • Norton HealthcareRecruiting
  • Massachusetts General HospitalRecruiting
  • Dana-Farber Cancer InstituteRecruiting
  • University of MichiganRecruiting
  • Memorial Sloan-Kettering Cancer CenterRecruiting
  • Mount Sinai HospitalRecruiting
  • Fox Chase Cancer Center
  • UPMC Hillman Cancer CenterRecruiting
  • University of Texas MD AndersonRecruiting
  • Inova Health Care ServicesRecruiting
  • Princess Alexandra Hospital OncologyRecruiting
  • Centro Catarinense de Pesquisa (CECAP) - Hospital Santa Catarina de BlumenauRecruiting
  • Instituto Nacional do CancerRecruiting
  • Centro Intergado de OncologiaRecruiting
  • Centro de Pesquisa Clinica em OncologiaRecruiting
  • Clinica De Neoplasias LitoralRecruiting
  • Hospital PaulistanoRecruiting
  • Princess Margaret Cancer CentreRecruiting
  • CHU de Bordeaux- Hopital Saint-AndreRecruiting
  • AP-HP Universite Paris SaclayRecruiting
  • CHU de LilleRecruiting
  • CHU Lyon-SudRecruiting
  • Hôpital de la Timone. Aix-Marseille UniversitéRecruiting
  • CHU MontpellierRecruiting
  • CHU de NantesRecruiting
  • Hôpital Saint Louis - APHPRecruiting
  • CHU de ToursRecruiting
  • Vivantes Network for Health Gmb, Neukölln ClinicRecruiting
  • Universitätsklinikum ErlangenRecruiting
  • Universitätsklinikum Essen (AöR)Recruiting
  • Nationales Centrum für Tumorerkrankungen NCTRecruiting
  • Uniklinik KolnRecruiting
  • Universitätsklinik RostockRecruiting
  • Universitats-Hautklinik TubingenRecruiting
  • Institute for Cancer Research and TreatmentRecruiting
  • Istituto Nazionale Tumori IRCCS Fondazione PascaleRecruiting
  • AUSL della RomagnaRecruiting
  • AOUS Le ScotteRecruiting
  • OSP Civile Maggiore Borgo TrentoRecruiting
  • National Cancer CenterRecruiting
  • Seoul National University HospitalRecruiting
  • Severance Hospital Yonsei University Health SystemRecruiting
  • University Medical Center GroningenRecruiting
  • Hospital Duran i ReynalsRecruiting
  • Hospital General Universitario Gregorio Marañn (Madrid)Recruiting
  • Complejo Hospitalario de NavarraRecruiting
  • Fundacio Investigao Hospital General Universitario de ValenciaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Cohort 1, Arm 1

Cohort 1, Arm 1b

Cohort 1, Arm 2b

Cohort 1, Arm 3

Cohort 1, Arm 5

Cohort 1 Expansion

Cohort 2, Arm 1 KRT-232 in combination with avelumab

Cohort 2, Arm 2 KRT-232 in combination with avelumab

Cohort 2 Expansion

Cohort 3

Cohort 4

Arm Description

KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 21-day cycle.

KRT-232 will be administered orally, once daily (QD) on Days 1-5 in a 23-day cycle.

KRT-232 will be administered orally, once daily (QD) on Days 1-5 in a 28-day cycle.

KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 21-day cycle.

KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle.

KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.

KRT-232 will be administered orally, once daily (QD) on Days 1-5, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.

KRT-232 will be administered orally, once daily (QD) on Days 1-7, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.

KRT-232 will be administered orally, once daily (QD) per RP2D dose and schedule, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.

KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.

KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.

Outcomes

Primary Outcome Measures

Cohort 1 Part 1: To determine the KRT-232 RP2D.
The Safety Review Committee (SRC) will determine RP2D for expansion based on safety and tolerability of each arm.
Cohort 1 Part 2: To determine the objective response rate (ORR) in subjects with p53WT MCC who have failed anti-PD-1 or anti-PDL-1 immunotherapy
ORR will be assessed per RECIST criteria version 1.1 after all subjects have been treated at the RP2D of KRT 232 and completed the second response assessment.
Cohort 2 Part 1: To determine the KRT-232 RP2D in combination with avelumab
DLTs will be used to establish the MTD of KRT-232 in combination with avelumab. SRC will determine the RP2D based on the safety of combination of KRT-232 with avelumab.
Cohort 2 Part 2: To determine the objective response rate (ORR) in treatment-naïve subjects with p53WT MCC
ORR will be assessed per RECIST criteria version 1.1 after all 30 subjects have been treated at the RP2D of in combination with avelumab and have completed the second response assessment.
Cohort 3: To determine the confirmed overall response rate (ORR) based on IRC assessments in subjects with p53WT MCC are chemotherapy naive and have failed anti-PD-1/PD-L.
ORR will be assessed per RECIST criteria 1.1 by IRC.
Cohort 4: To determine the confirmed overall response rate (ORR) based on IRC assessments in subjects with p53WT MCC who have failed anti-PD-1 or anti-PDL-1 immunotherapy and have had least 1 line of prior chemotherapy.
ORR will be assessed per RECIST criteria 1.1 by IRC.

Secondary Outcome Measures

To determine the confirmed ORR based on investigator assessment.
ORR will be assessed per RECIST criteria 1.1 by investigators.
To determine the duration of response (DoR)
Time from documentation of response (CR or PR as determined by RECIST 1.1) until disease progression.
To determine Progression-free survival (PFS)
Time from initial treatment until disease progression.
To determine overall survival (OS)
Time from initial treatment until death from any cause.
To determine clinical benefit rate (CBR)
PR, CR or stable disease that last at least 10 weeks, per IRC or investigator assessment.

Full Information

First Posted
December 6, 2018
Last Updated
February 28, 2023
Sponsor
Kartos Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03787602
Brief Title
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
Official Title
A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 19, 2019 (Actual)
Primary Completion Date
November 2024 (Anticipated)
Study Completion Date
August 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kartos Therapeutics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Merkel Cell Carcinoma
Keywords
navtemadlin (KRT-232)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
115 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1, Arm 1
Arm Type
Experimental
Arm Description
KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 21-day cycle.
Arm Title
Cohort 1, Arm 1b
Arm Type
Experimental
Arm Description
KRT-232 will be administered orally, once daily (QD) on Days 1-5 in a 23-day cycle.
Arm Title
Cohort 1, Arm 2b
Arm Type
Experimental
Arm Description
KRT-232 will be administered orally, once daily (QD) on Days 1-5 in a 28-day cycle.
Arm Title
Cohort 1, Arm 3
Arm Type
Experimental
Arm Description
KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 21-day cycle.
Arm Title
Cohort 1, Arm 5
Arm Type
Experimental
Arm Description
KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle.
Arm Title
Cohort 1 Expansion
Arm Type
Experimental
Arm Description
KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.
Arm Title
Cohort 2, Arm 1 KRT-232 in combination with avelumab
Arm Type
Experimental
Arm Description
KRT-232 will be administered orally, once daily (QD) on Days 1-5, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.
Arm Title
Cohort 2, Arm 2 KRT-232 in combination with avelumab
Arm Type
Experimental
Arm Description
KRT-232 will be administered orally, once daily (QD) on Days 1-7, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.
Arm Title
Cohort 2 Expansion
Arm Type
Experimental
Arm Description
KRT-232 will be administered orally, once daily (QD) per RP2D dose and schedule, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.
Arm Title
Cohort 3
Arm Type
Experimental
Arm Description
KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.
Arm Title
Cohort 4
Arm Type
Experimental
Arm Description
KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.
Intervention Type
Drug
Intervention Name(s)
KRT-232
Other Intervention Name(s)
navtemadlin
Intervention Description
KRT-232 is an experimental MDM2 anticancer drug taken by mouth.
Intervention Type
Drug
Intervention Name(s)
Avelumab
Other Intervention Name(s)
Bavencio
Intervention Description
Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.
Primary Outcome Measure Information:
Title
Cohort 1 Part 1: To determine the KRT-232 RP2D.
Description
The Safety Review Committee (SRC) will determine RP2D for expansion based on safety and tolerability of each arm.
Time Frame
10 Weeks
Title
Cohort 1 Part 2: To determine the objective response rate (ORR) in subjects with p53WT MCC who have failed anti-PD-1 or anti-PDL-1 immunotherapy
Description
ORR will be assessed per RECIST criteria version 1.1 after all subjects have been treated at the RP2D of KRT 232 and completed the second response assessment.
Time Frame
10 Weeks
Title
Cohort 2 Part 1: To determine the KRT-232 RP2D in combination with avelumab
Description
DLTs will be used to establish the MTD of KRT-232 in combination with avelumab. SRC will determine the RP2D based on the safety of combination of KRT-232 with avelumab.
Time Frame
28 Days
Title
Cohort 2 Part 2: To determine the objective response rate (ORR) in treatment-naïve subjects with p53WT MCC
Description
ORR will be assessed per RECIST criteria version 1.1 after all 30 subjects have been treated at the RP2D of in combination with avelumab and have completed the second response assessment.
Time Frame
10 Weeks
Title
Cohort 3: To determine the confirmed overall response rate (ORR) based on IRC assessments in subjects with p53WT MCC are chemotherapy naive and have failed anti-PD-1/PD-L.
Description
ORR will be assessed per RECIST criteria 1.1 by IRC.
Time Frame
10 Weeks
Title
Cohort 4: To determine the confirmed overall response rate (ORR) based on IRC assessments in subjects with p53WT MCC who have failed anti-PD-1 or anti-PDL-1 immunotherapy and have had least 1 line of prior chemotherapy.
Description
ORR will be assessed per RECIST criteria 1.1 by IRC.
Time Frame
10 Weeks
Secondary Outcome Measure Information:
Title
To determine the confirmed ORR based on investigator assessment.
Description
ORR will be assessed per RECIST criteria 1.1 by investigators.
Time Frame
1 year after last subject enrolled.
Title
To determine the duration of response (DoR)
Description
Time from documentation of response (CR or PR as determined by RECIST 1.1) until disease progression.
Time Frame
1 year after last subject enrolled
Title
To determine Progression-free survival (PFS)
Description
Time from initial treatment until disease progression.
Time Frame
1 year after last subject enrolled
Title
To determine overall survival (OS)
Description
Time from initial treatment until death from any cause.
Time Frame
1 year after last subject enrolled
Title
To determine clinical benefit rate (CBR)
Description
PR, CR or stable disease that last at least 10 weeks, per IRC or investigator assessment.
Time Frame
1 year after last subject enrolled.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: For Cohort 1, 3 and 4 patients must have failed treatment with at least one PD-1 inhibitor or PD-L1 inhibitor for metastatic MCC For Cohort 2, patients must not have received any anti-PD-1 or anti-PD-L1 therapy For Cohort 3, patients must not have received any prior chemotherapy For Cohort 4, patients must have received at least one prior line of chemotherapy ECOG performance status of 0 to 1 Histologically confirmed MCC. Disease must be measurable, with at least 1 measurable lesion by RECIST 1.1 MCC expressing p53WT based on any CLIA or test approved by local health authority or a validated test (Cohort 1 and 2) MCC expressing p53WT based Central Lab test (Cohort 3 and 4) Adequate hematological, hepatic, and renal functions Exclusion Criteria: For Cohort 2, subjects must not have autoimmune disease, medical conditions requiring systemic immunosuppression, prior stem cell transplant, or active infection with HBV or HCV. Patients previously treated with MDM2 antagonist therapies or p53-directed therapies History of major organ transplant Patients with known central nervous system (CNS) metastases that are previously untreated Grade 2 or higher QTc prolongation (>480 milli-seconds per NCI-CTCAE criteria, version 5.0)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
John Mei
Phone
650-542-0136
Email
jmei@kartosthera.com
First Name & Middle Initial & Last Name or Official Title & Degree
Emily Houlihan
Phone
401-954-8042
Email
ehoulihan@kartosthera.com
Facility Information:
Facility Name
University of Colorado Anschutz Medical Campus
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Name
Miami Cancer Institute
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
Individual Site Status
Recruiting
Facility Name
Moffitt
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Individual Site Status
Recruiting
Facility Name
Northwestern Memorial Hospital
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Individual Site Status
Recruiting
Facility Name
Norton Healthcare
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Norton Cancer Institute Research
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215-5418
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Individual Site Status
Recruiting
Facility Name
Memorial Sloan-Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Individual Site Status
Recruiting
Facility Name
Mount Sinai Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Recruiting
Facility Name
Fox Chase Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19111-2434
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
UPMC Hillman Cancer Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Texas MD Anderson
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Name
Inova Health Care Services
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Name
Princess Alexandra Hospital Oncology
City
Woolloongabba
Country
Australia
Individual Site Status
Recruiting
Facility Name
Centro Catarinense de Pesquisa (CECAP) - Hospital Santa Catarina de Blumenau
City
Blumenau
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Instituto Nacional do Cancer
City
Brasília
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Centro Intergado de Oncologia
City
Curitiba
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Centro de Pesquisa Clinica em Oncologia
City
Ijuí
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Clinica De Neoplasias Litoral
City
Itajai
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Hospital Paulistano
City
São Paulo
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Princess Margaret Cancer Centre
City
Toronto
Country
Canada
Individual Site Status
Recruiting
Facility Name
CHU de Bordeaux- Hopital Saint-Andre
City
Bordeaux
Country
France
Individual Site Status
Recruiting
Facility Name
AP-HP Universite Paris Saclay
City
Gif-sur-Yvette
Country
France
Individual Site Status
Recruiting
Facility Name
CHU de Lille
City
Lille
Country
France
Individual Site Status
Recruiting
Facility Name
CHU Lyon-Sud
City
Lyon
Country
France
Individual Site Status
Recruiting
Facility Name
Hôpital de la Timone. Aix-Marseille Université
City
Marseille
ZIP/Postal Code
Cedex 5
Country
France
Individual Site Status
Recruiting
Facility Name
CHU Montpellier
City
Montpellier
Country
France
Individual Site Status
Recruiting
Facility Name
CHU de Nantes
City
Nantes
Country
France
Individual Site Status
Recruiting
Facility Name
Hôpital Saint Louis - APHP
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Name
CHU de Tours
City
Tours
Country
France
Individual Site Status
Recruiting
Facility Name
Vivantes Network for Health Gmb, Neukölln Clinic
City
Berlin
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitätsklinikum Erlangen
City
Erlangen
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitätsklinikum Essen (AöR)
City
Essen
Country
Germany
Individual Site Status
Recruiting
Facility Name
Nationales Centrum für Tumorerkrankungen NCT
City
Heidelberg
Country
Germany
Individual Site Status
Recruiting
Facility Name
Uniklinik Koln
City
Köln
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitätsklinik Rostock
City
Rostock
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitats-Hautklinik Tubingen
City
Tübingen
Country
Germany
Individual Site Status
Recruiting
Facility Name
Institute for Cancer Research and Treatment
City
Candiolo
Country
Italy
Individual Site Status
Recruiting
Facility Name
Istituto Nazionale Tumori IRCCS Fondazione Pascale
City
Napoli
Country
Italy
Individual Site Status
Recruiting
Facility Name
AUSL della Romagna
City
Ravenna
Country
Italy
Individual Site Status
Recruiting
Facility Name
AOUS Le Scotte
City
Siena
Country
Italy
Individual Site Status
Recruiting
Facility Name
OSP Civile Maggiore Borgo Trento
City
Verona
Country
Italy
Individual Site Status
Recruiting
Facility Name
National Cancer Center
City
Goyang-si
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Seoul National University Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Severance Hospital Yonsei University Health System
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
University Medical Center Groningen
City
Groningen
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Hospital Duran i Reynals
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital General Universitario Gregorio Marañn (Madrid)
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
Complejo Hospitalario de Navarra
City
Pamplona
Country
Spain
Individual Site Status
Recruiting
Facility Name
Fundacio Investigao Hospital General Universitario de Valencia
City
Valencia
Country
Spain
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

We'll reach out to this number within 24 hrs